Key result
Low molecular weight heparin therapy used among pregnant women for various indications was associated with an 89% live birth rate and no thromboembolic events.
Why the study?
Does enoxaparin therapy during pregnancy result in safe and successful pregnancy outcomes in women with indications for anticoagulation?
Population
100 pregnant women receiving low molecular weight heparin for various indications.
Design
Cohort
Authors
Loading...
May support LMWH safety in pregnancy; leaves open need for randomized confirmation before practice change.
Observational (n=100)
No
Does enoxaparin therapy during pregnancy result in safe and successful pregnancy outcomes in women with indications for anticoagulation?
Enoxaparin use during pregnancy for various indications, including mechanical valves and DVT, appears safe and is associated with successful pregnancy outcomes without major thromboembolic or bleeding complications.
Singh et al. (2018) conducted an observational in Pregnancy requiring anticoagulation therapy (n=100). Low molecular weight heparin (Enoxaparin) was evaluated on Live birth rate. Low molecular weight heparin therapy used among pregnant women for various indications was associated with an 89% live birth rate and no thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: